Anebulo Pharmaceuticals Stock Current Liabilities

ANEB Stock  USD 1.46  0.04  2.67%   
Anebulo Pharmaceuticals fundamentals help investors to digest information that contributes to Anebulo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Anebulo Stock. The fundamental analysis module provides a way to measure Anebulo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anebulo Pharmaceuticals stock.
The current year's Total Current Liabilities is expected to grow to about 390.1 K, whereas Non Current Liabilities Total is forecasted to decline to about 98.9 K.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Anebulo Pharmaceuticals Company Current Liabilities Analysis

Anebulo Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

 = 

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis

Anebulo Current Liabilities Driver Correlations

Understanding the fundamental principles of building solid financial models for Anebulo Pharmaceuticals is extremely important. It helps to project a fair market value of Anebulo Stock properly, considering its historical fundamentals such as Current Liabilities. Since Anebulo Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Anebulo Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Anebulo Pharmaceuticals' interrelated accounts and indicators.

Anebulo Current Liabilities Historical Pattern

Today, most investors in Anebulo Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Anebulo Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Anebulo Pharmaceuticals current liabilities as a starting point in their analysis.
   Anebulo Pharmaceuticals Current Liabilities   
       Timeline  
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition

Anebulo Total Current Liabilities

Total Current Liabilities

390,094

At present, Anebulo Pharmaceuticals' Total Current Liabilities is projected to increase significantly based on the last few years of reporting.
In accordance with the recently published financial statements, Anebulo Pharmaceuticals has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.

Did you try this?

Run Funds Screener Now

   

Funds Screener

Find actively-traded funds from around the world traded on over 30 global exchanges
All  Next Launch Module

Anebulo Fundamentals

About Anebulo Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Anebulo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anebulo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anebulo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:
Check out Anebulo Pharmaceuticals Piotroski F Score and Anebulo Pharmaceuticals Altman Z Score analysis.
For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.32)
Return On Assets
(0.66)
Return On Equity
(1.14)
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.